News | April 28, 2022
Sanofi continues to deliver strong business
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
New kit enhances menu of FFPE solutions and allows oncology researchers to extract higher yields of concentrated DNA compared to traditional techniques
The launch is yet another first of its kind innovation in India
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
India-Sweden Healthcare Innovation Centre in collaboration with AIIMS Jodhpur and AstraZeneca India launches an e-learning Upskilling Program in Diabetes Management for nurses
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Subscribe To Our Newsletter & Stay Updated
